NYSE:ANVS

Annovis Bio News Headlines

$26.54
+0.03 (+0.11 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$25.25
Now: $26.54
$26.87
50-Day Range
$24.86
MA: $29.36
$38.44
52-Week Range
$2.93
Now: $26.54
$47.99
Volume133,126 shs
Average Volume301,579 shs
Market Capitalization$184.37 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Annovis Bio (NYSE ANVS) News Headlines Today

SourceHeadline
Annovis Bio (NYSE:ANVS)  Shares Down 8.7% Annovis Bio (NYSE:ANVS) Shares Down 8.7%
americanbankingnews.com - April 8 at 12:42 AM
Annovis Bio (NYSE:ANVS) Shares Gap Down to $33.30Annovis Bio (NYSE:ANVS) Shares Gap Down to $33.30
americanbankingnews.com - March 17 at 2:48 PM
Annovis Bio Stock Is Trading Higher After Parkinsons Med Shows Improvement In Speed, CoordinationAnnovis Bio Stock Is Trading Higher After Parkinson's Med Shows Improvement In Speed, Coordination
finance.yahoo.com - March 16 at 1:50 PM
Annovis Bio (NYSE:ANVS) Shares Gap Up to $34.00Annovis Bio (NYSE:ANVS) Shares Gap Up to $34.00
americanbankingnews.com - March 16 at 11:27 AM
Annovis Bio to Present at the H.C. Wainwright Global Life Sciences ConferenceAnnovis Bio to Present at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 9 at 7:56 AM
Annovis Bio to Present at the BIO CEO & Investor Digital ConferenceAnnovis Bio to Present at the BIO CEO & Investor Digital Conference
finance.yahoo.com - February 16 at 7:17 AM
Annovis Bio Receives European Patent for Method of Treating Acute Nerve and Brain InsultsAnnovis Bio Receives European Patent for Method of Treating Acute Nerve and Brain Insults
finance.yahoo.com - February 4 at 7:29 AM
Annovis Bios Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice StudyAnnovis Bio's Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice Study
finance.yahoo.com - February 2 at 7:26 AM
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.